2,83% in the red was my portfolio today.
How much were you in the red?
$VUSA (+1%)
$ALUR
$DPRO
$FFIE
$F (-1.21%)
$EXSA (+0.97%)
$IWDA (+1.17%)
$SOFI (+0%)
$TENX
$UGI (+1.01%)
TENTenax TherapeutUS88032L6056TENXTENX
TEN
Tenax Therapeut
US88032L6056
TENX
TENX
Financials
Market Cap
$12.31M5Y beta
2.22EPS (TTM)
-$22.35Free Float
3.40MEBITDA (TTM)
-$13.03MFree Cashflow (TTM)
-$11.45MPricing
52W span
$2.77$61.20
Analyst Ratings
The price target is $32.50 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
5Biotechnology & DrugsHealth Care
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Identifier
ISIN
US88032L6056
Primary Ticker
TENX